Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab-Reference-Cited by-同舟云学术

Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab

Published:2019-05-16 Issue: Volume: Page:
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:
Short-container-title:mol clin onc

Author:

Giannicola Rocco¹,D'Arrigo Graziella²,Botta Cirino³,Agostino Rita¹,Del Medico Pietro¹,Falzea Antonia¹,Barbieri Vito³,Staropoli Nicoletta³,Del Giudice Teresa³,Pastina Pierpaolo⁴,Nardone Valerio⁴,Monoriti Marika⁵,Calabrese Graziella⁶,Tripepi Giovanni²,Pirtoli Luigi⁴,Tassone Pierfrancesco³,Tagliaferri Pierosandro³,Correale Pierpaolo¹

Affiliation:

1. Medical Oncology Unit, ‘Bianchi‑Melacrino‑Morelli’ Grand Metropolitan Hospital, I‑89124 Reggio di Calabria, Italy

2. Statistical Unit, National Council of Research (CNR), Grand Metropolitan Hospital‑IFC, I‑89124 Reggio di Calabria, Italy

3. Medical Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, I‑88100 Catanzaro, Italy

4. Radiation Oncology Unit, Siena University Hospital, I‑53100 Siena, Italy

5. Autoimmunity Laboratory, ‘Bianchi‑Melacrino‑Morelli’ Grand Metropolitan Hospital, I‑89124 Reggio di Calabria, Italy

6. Radiology Unit, ‘Bianchi‑Melacrino‑Morelli’ Grand Metropolitan Hospital, I‑89124 Reggio di Calabria, Italy

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma;Journal for ImmunoTherapy of Cancer;2024-06

2. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events;Rheumatic Disease Clinics of North America;2024-05

3. Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort;Clinical and Experimental Medicine;2024-04-10

4. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors;Cancers;2024-03-20

5. B cell clonality in cancer;Seminars in Immunology;2024-03